文献速递甲状腺核医学核素与放射性配体治疗

重组人促甲状腺激素与甲状腺激素撤退在转移性分化型甲状腺癌131I治疗中基于124I PET/CT剂量学的比较

Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer.
PubMed 文献 · J Nucl Med · 2017-01-19

本研究在4例转移性分化型甲状腺癌患者中,比较同一患者分别经甲状腺激素撤退(THW)和重组人促甲状腺激素(rhTSH)准备后,用124I PET/CT剂量学估算131I治疗时关键器官和肿瘤的吸收剂量。结果显示两种准备方法间正常器官每MBq 131I吸收剂量患者间变异大,THW准备下肿瘤与骨髓吸收剂量比值(治疗指数)高于rhTSH准备。作者认为需进一步比较后才能就rhTSH与THW准备方法得出明确结论。

要点

  • 4例转移性分化型甲状腺癌患者先后经rhTSH和THW准备后行124I PET/CT剂量学检查。
  • THW与rhTSH的器官吸收剂量比值患者间差异大,前3例5个器官均值分别为1.5、2.5、0.64,第4例3个器官均值为1.1。
  • 除1例患者的3个病灶外,THW研究中的肿瘤每单位给药活度131I吸收剂量高于rhTSH研究。

核心结论

  • 结果提示两种促甲状腺激素刺激方法间,每MBq 131I给药后正常器官总吸收剂量患者间变异大。
  • 肿瘤与剂量限制器官(骨髓)吸收剂量比值即治疗指数,在THW辅助给药时高于rhTSH辅助给药时。
  • 在就rhTSH与THW患者准备方法用于转移性分化型甲状腺癌131I治疗得出明确结论前,需要对同时使用两种方法准备的患者进行肿瘤和正常器官吸收剂量的额外比较。

研究设计与样本

  • 研究纳入MedStar Washington Hospital Center的4例转移性分化型甲状腺癌患者。
  • 患者先经rhTSH方法准备,给予约30-63 MBq 124I后2、24、48、72、96小时行124I PET/CT显像。
  • 5-8周后同一批患者经THW方法准备并同前显像。
  • 作为前瞻性研究一部分获取的124I PET/CT图像用于回顾性剂量学计算,使用3D-RD剂量学软件包估算131I治疗时正常器官吸收剂量。
  • 获取每次研究(rhTSH和THW)中肺、肝、心脏、肾脏和骨髓的131I吸收剂量;在3例患者中识别22个病灶,于每次研究每幅PET图像上勾画轮廓,计算时间积分活度系数并输入OLINDA/EXM球体剂量计算器获得肿瘤吸收剂量。

主要发现

  • 前3例患者THW与rhTSH的5个器官吸收剂量比值均值分别为1.5、2.5和0.64,第4例患者3个器官比值均值为1.1。
  • 骨髓每单位给药活度吸收剂量在rhTSH后分别为0.13、0.086、0.33和0.068 mGy/MBq,在THW后分别为0.11、0.14、0.22和0.080 mGy/MBq(对应每例患者)。
  • 除1例患者的3个病灶外,THW研究中肿瘤每单位给药活度131I吸收剂量高于rhTSH研究。
  • THW刺激后与rhTSH刺激后平均肿瘤吸收剂量比值在患者1、患者2和患者3分别为3.9、27和1.4。
  • THW和rhTSH后平均肿瘤与骨髓每单位给药活度131I吸收剂量比值分别为232和62(患者1)、12和0.78(患者2)、22和11(患者3)。

局限性

  • 作者指出,在就rhTSH与THW患者准备方法用于转移性分化型甲状腺癌131I治疗得出明确结论前,需要对同时使用两种方法准备的患者进行肿瘤和正常器官吸收剂量的额外比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with metastatic differentiated thyroid cancer (DTC) may be prepared using either thyroid-stimulating hormone withdrawal (THW) or recombinant human thyroid-stimulating hormone (rhTSH) injections before 131I administration for treatment. The objective of this study was to compare the absorbed dose to the critical organs and tumors determined by 124I PET/CT-based dosimetry for 131I therapy of metastatic DTC when the same patient was prepared with and imaged after both THW and rhTSH injections. Methods: Four DTC patients at MedStar Washington Hospital Center were first prepared using the rhTSH method and imaged by 124I PET/CT at 2, 24, 48, 72, and 96 h after administration of approximately 30-63 MBq of 124I. After 5-8 wk, the same patients were prepared using the THW method and imaged as before. The 124I PET/CT images acquired as part of a prospective study were used to perform retrospective dosimetric calculations for 131I therapy for the normal organs with the dosimetry package 3D-RD. The absorbed doses from 131I for the lungs, liver, heart, kidneys, and bone marrow were obtained for each study (rhTSH and THW). Twenty-two lesions in 3 patients were identified. The contours were drawn on each PET image of each study. Time-integrated activity coefficients were calculated and used as input in OLINDA/EXM sphere dose calculator to obtain the absorbed dose to tumors. Results: The THW-to-rhTSH organ absorbed dose ratio averaged over 5 organs for the first 3 patients was 1.5, 2.5, and 0.64, respectively, and averaged over 3 organs for the fourth patient was 1.1. The absorbed dose per unit administered activity to the bone marrow was 0.13, 0.086, 0.33, and 0.068 mGy/MBq after rhTSH and 0.11, 0.14, 0.22, and 0.080 mGy/MBq after THW for each patient, respectively. With the exception of 3 lesions of 1 patient, the absorbed dose per unit administered activity of 131I was higher in the THW study than in the rhTSH study. The ratio of the average tumor absorbed dose after stimulation by THW compared with stimulation by rhTSH injections was 3.9, 27, and 1.4 for patient 1, patient 2, and patient 3, respectively. The ratio of mean tumor to bone marrow absorbed dose per unit administered activity of 131I, after THW and rhTSH, was 232 and 62 (patient 1), 12 and 0.78 (patient 2), and 22 and 11 (patient 3), respectively. Conclusion: The results suggest a high patient variability in the overall absorbed dose to the normal organs per MBq of 131I administered, between the 2 TSH stimulation methods. The tumor-to-dose-limiting-organ (bone marrow) absorbed dose ratio, that is, the therapeutic index, was higher in the THW-aided than rhTSH-aided administrations. Additional comparison for tumor and normal organ absorbed dose in patients prepared using both methods is needed before definitive conclusions may be drawn regarding rhTSH versus THW patient preparation methods for 131I therapy of metastatic DTC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Plyku D, Hobbs RF, Huang K, et al. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer. J Nucl Med. 2017. PMID: 28104741. doi:10.2967/jnumed.116.179366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。